<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047630</url>
  </required_header>
  <id_info>
    <org_study_id>C13-11-1242</org_study_id>
    <nct_id>NCT02047630</nct_id>
  </id_info>
  <brief_title>Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare efficacy and tolerability of the&#xD;
      brand-name latanoprost and one of its generic version in subjects with primary open angle&#xD;
      glaucoma or ocular hypertension.&#xD;
&#xD;
      This randomized, double-blinded, cross-over design study has a 4 months follow-up. There are&#xD;
      two periods of 8 weeks. During the first period, subjects put brand-name latanoprost in one&#xD;
      eye and the generic version in the other one. In the second period, drops are switched from&#xD;
      one eye to the other. There are intraocular pressure measurements (diurnal curves) on day 0&#xD;
      (before treatment), at 8 weeks (at the end of first period) and at 16 weeks (at the end of&#xD;
      second period). Variations of intraocular pressure in each eye will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Problem with IP supply&#xD;
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 4, 2014</completion_date>
  <primary_completion_date type="Actual">December 4, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Intraocular Pressure (IOP)</measure>
    <time_frame>8 weeks, 16 weeks</time_frame>
    <description>Goldman applanation tonometry will be used to measure IOP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Conjunctival hyperemia</measure>
    <time_frame>8 weeks, 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in corneal staining</measure>
    <time_frame>8 weeks, 16 weeks</time_frame>
    <description>Oxford grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TSS-IOP (Treatment Satisfaction Survey for IntraOcular Pressure)</measure>
    <time_frame>8 weeks, 16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Generic latanoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 eye drop hs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brand-name latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 eye drop hs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic latanoprost</intervention_name>
    <arm_group_label>Brand-name latanoprost</arm_group_label>
    <arm_group_label>Generic latanoprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brand-name latanoprost</intervention_name>
    <arm_group_label>Brand-name latanoprost</arm_group_label>
    <arm_group_label>Generic latanoprost</arm_group_label>
    <other_name>Xalatan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt;18 years old&#xD;
&#xD;
          2. Primary open angle glaucoma, glaucoma suspect or ocular hypertension&#xD;
&#xD;
          3. Bilateral&#xD;
&#xD;
          4. Without any treatment or treated with latanoprost or another prostaglandin analog&#xD;
&#xD;
          5. Intraocular pressure &gt;21mmHg (without treatment or after a washout period)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intraocular pressure &gt;30mmHg&#xD;
&#xD;
          2. Secondary glaucoma (uveitic, neovascular, traumatic ) or congenital glaucoma&#xD;
&#xD;
          3. Pseudoexfoliation syndrome&#xD;
&#xD;
          4. Pigmentary dispersion syndrome or Pigmentary glaucoma&#xD;
&#xD;
          5. Severe glaucoma; Cup-to-disc ratio ≥9/10 OU Loss of central visual field (central 10°)&#xD;
&#xD;
          6. Use of other topical medication to lower intraocular pressure&#xD;
&#xD;
          7. Pregnancy and breast-feeding&#xD;
&#xD;
          8. Being allergic to latanoprost or benzalkonium chloride (BAK)&#xD;
&#xD;
          9. Current use of acetazolamide (Diamox)&#xD;
&#xD;
         10. Changes of systemic doses of beta-blockers during study&#xD;
&#xD;
         11. Recent use of topical corticosteroids (&lt;1 month)&#xD;
&#xD;
         12. Contact lens wearer&#xD;
&#xD;
         13. Closed angle at gonioscopy or past angle closure glaucoma&#xD;
&#xD;
         14. Filtration surgery (example. : trabeculectomy)&#xD;
&#xD;
         15. Selective Laser Trabeculoplasty (SLT) or Argon Laser Trabeculoplasty(ALT)&#xD;
&#xD;
         16. Recent Intraocular surgery (&lt;3 months)&#xD;
&#xD;
         17. Refractive surgery&#xD;
&#xD;
         18. Recent iridotomy or capsulotomy (&lt;3 months)&#xD;
&#xD;
         19. Past medical history of ocular trauma (example : angle recession)&#xD;
&#xD;
         20. Past or active uveitis&#xD;
&#xD;
         21. Herpetic keratitis&#xD;
&#xD;
         22. Monocular vision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Josée Fredette, MD, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du CHU de Québec; Université Laval</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre universitaire d'ophtalmologie, Hôpital du Saint-Sacrement, CHU de Québec</name>
      <address>
        <city>Québec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>January 19, 2014</study_first_submitted>
  <study_first_submitted_qc>January 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>July 23, 2017</last_update_submitted>
  <last_update_submitted_qc>July 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHU de Quebec-Universite Laval</investigator_affiliation>
    <investigator_full_name>Marie-Josée Fredette</investigator_full_name>
    <investigator_title>MD, FRCSC</investigator_title>
  </responsible_party>
  <keyword>Primary open angle glaucoma</keyword>
  <keyword>Ocular hypertension</keyword>
  <keyword>latanoprost</keyword>
  <keyword>generic</keyword>
  <keyword>intraocular pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

